Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

Slides:

Advertisements

Similar presentations

A ggrastat- Phase of the AGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination.

Advertisements

VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.

HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.

The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.

Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.

GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.

VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Heparin Should be the First-line Therapy for Patients with ACS/AMI

The American College of Cardiology Presented by Dr. Adnan Kastrati

Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.

For the HORIZONS-AMI Investigators

Management of ST-Elevation Myocardial Infarction

Antiplatelet Therapy For STEMI: The Case for Cangrelor

The DANAMI-2 Trial Danish Trial in Acute Myocardial Infarction-2

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Emerging Data on ACS Management From ACC

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Selecting NOACs for High-Risk Patients

Tailoring Antiplatelet Therapy in PCI

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?

Treatment Options to Consider

NOACS: Emerging data in ACS/IHD

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

Thank you for taking the pre-assessment

Section F: Clinical guidelines

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Practical Considerations to Extend Treatment for VTE

For the HORIZONS-AMI Investigators

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

A Case Challenge.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in PAD

Managing Pulmonary Embolism Posthospital Discharge

Intermediate/low-risk UA

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Nat. Rev. Cardiol. doi: /nrcardio

Improving Adherence to Antiplatelet Therapy After an ACS Event

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

ESC Guideline on the Management of STEMI Recommendation for DAPT

Section C: Clinical trial update: Oral antiplatelet therapy

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Comparison of US and European Guidelines

Oral Antiplatelet Therapy in Primary PCI/STEMI

GP IIb/IIIa Inhibitors in Primary PCI/STEMI

EUROMAX Bleeding Outcomes at 30 d

HORIZONS-AMI Bleeding Outcomes at 30 d in a Primary PCI Population

CHAMPION PHOENIX Primary Efficacy Outcomes at 48 h, MITT

Anticoagulation in Primary PCI/STEMI

FUTURA/OASIS 8

Oral Antiplatelet Therapy in Non-ST Elevation ACS

CHARISMA Bleeding End Points by Baseline Daily Aspirin Dose

CURRENT Efficacy and Bleeding by Aspirin Dose

EARLY-ACS Bleeding Outcomes at 30 days

GP IIb/IIIa Inhibitors in Primary PCI/Non-ST-segment Elevation ACS

PLATO Subanalysis Efficacy and Safety End Points

Anticoagulation in Non-ST-segment Elevation ACS

OASIS 5 -- Cumulative Risk of Death, MI, or Refractory Ischemia

The Future for ACS Management?

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)